490 related articles for article (PubMed ID: 32973816)
21. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
Ning P; Liu S; Cao H
J Med Case Rep; 2024 Jan; 18(1):51. PubMed ID: 38247005
[TBL] [Abstract][Full Text] [Related]
22. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
[TBL] [Abstract][Full Text] [Related]
23. Sintilimab-induced autoimmune diabetes: A case report and review of the literature.
Yang J; Wang Y; Tong XM
World J Clin Cases; 2022 Feb; 10(4):1263-1277. PubMed ID: 35211559
[TBL] [Abstract][Full Text] [Related]
24. Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report.
Fu L; Chen P; Wang S; Liu W; Chen Z; Chen H; Fu Z
Anticancer Drugs; 2022 Jan; 33(1):e741-e746. PubMed ID: 34338239
[TBL] [Abstract][Full Text] [Related]
25. Sick sinus syndrome associated with anti-programmed cell death-1.
Hsu CY; Su YW; Chen SC
J Immunother Cancer; 2018 Jul; 6(1):72. PubMed ID: 30012209
[TBL] [Abstract][Full Text] [Related]
26. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
Changizzadeh PN; Mukkamalla SKR; Armenio VA
J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
[TBL] [Abstract][Full Text] [Related]
27. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
Harsch IA; Konturek PC
Wiad Lek; 2018; 71(5):945-948. PubMed ID: 30176620
[TBL] [Abstract][Full Text] [Related]
28. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
Gunjur A; Klein O; Kee D; Cebon J
J Immunother Cancer; 2019 Sep; 7(1):241. PubMed ID: 31488221
[TBL] [Abstract][Full Text] [Related]
29. Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies.
Way J; Drakaki A; Drexler A; Freeby M
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28978581
[TBL] [Abstract][Full Text] [Related]
30. Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.
Abdullah HMA; Elnair R; Khan UI; Omar M; Morey-Vargas OL
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31451458
[TBL] [Abstract][Full Text] [Related]
31. [Clinical characteristics of immune checkpoint inhibitor-related type 1 diabetes mellitus].
Qiu JL; Luo SM; Yin WF; Li X; Zhou ZG
Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(1):38-41. PubMed ID: 36594136
[TBL] [Abstract][Full Text] [Related]
32. Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review.
Huang W; Liu Y; Li M; Xue Y; Bao W; Guo Y
Medicine (Baltimore); 2023 Nov; 102(45):e35946. PubMed ID: 37960733
[TBL] [Abstract][Full Text] [Related]
33. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
Hickmott L; De La Peña H; Turner H; Ahmed F; Protheroe A; Grossman A; Gupta A
Target Oncol; 2017 Apr; 12(2):235-241. PubMed ID: 28255845
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
Goff CB; Plaxe SC; White W; Dasanu CA
J Oncol Pharm Pract; 2023 Jul; 29(5):1259-1263. PubMed ID: 36734125
[TBL] [Abstract][Full Text] [Related]
35. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
Matsuura N; Koh G; Konishi C; Minamino S; Takahara Y; Harada H; Kodama K; Emoto M
Cancer Immunol Immunother; 2018 Sep; 67(9):1417-1424. PubMed ID: 29995236
[TBL] [Abstract][Full Text] [Related]
36. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.
Wang J; Fei K; Jing H; Wu Z; Wu W; Zhou S; Ni H; Chen B; Xiong Y; Liu Y; Peng B; Yu D; Jiang H; Liu J
MAbs; 2019; 11(8):1443-1451. PubMed ID: 31402780
[TBL] [Abstract][Full Text] [Related]
37. The clinical application of camrelizumab on advanced hepatocellular carcinoma.
Chen Z; Lu X; Koral K
Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1017-1024. PubMed ID: 32762583
[TBL] [Abstract][Full Text] [Related]
38. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report.
Edahiro R; Ishijima M; Kurebe H; Nishida K; Uenami T; Kanazu M; Akazawa Y; Yano Y; Mori M
Thorac Cancer; 2019 May; 10(5):1276-1279. PubMed ID: 30964601
[TBL] [Abstract][Full Text] [Related]
39. Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.
Liu X; Yi Y
Immunotherapy; 2021 Dec; 13(17):1387-1393. PubMed ID: 34665016
[TBL] [Abstract][Full Text] [Related]
40. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]